Mantle cell lymphoma

详细信息	查看全文 | 推荐本文 |

• 作者：Sergio Cortelazzo^a  ; [Author Vitae] ; Maurilio Ponzoni^b ; ^c  ; [Author Vitae] ; André ; s J.M. Ferreri^c ; ^d ; ^{andres.ferreri@hsr.it} ; ^{start@istitutotumori.mi.it}  ; [Author Vitae] ; Martin Dreyling^e  ; [Author Vitae]
• 关键词：B-cell lymphomas ; Cyclin D1 ; bcl-1 ; Allogeneic transplantation
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2012
• 期刊代码：73_10408428
• 类别：med
• 出版时间：April, 2012
• 卷：82
• 期：1
• 页码：78-101
• 文件大小：620 K

摘要

MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to conventional chemotherapy has increased overall response rates, but it does not improve overall survival with respect to chemotherapy alone. The use of intensive frontline therapies including rituximab and consolidated by ASCT ameliorates response rate and prolongs progression-free survival, but any impact on survival remains to be proven. Furthermore, the optimal timing, cytoreductive regimen and conditioning regimen, and the clinical implications of achieving a disease remission even at molecular level remain to be elucidated. The development of targeted therapies as the consequence of better dissection of pathogenetic pathways in MCL might improve the outcome of conventional chemotherapy in most patients and spare the toxicity of intense therapy in a minority of MCL patients characterized by a relatively indolent disease. Patients not eligible for intensive regimens, such as hyperC-VAD, may be considered for less demanding therapies, such as the combination of rituximab either with CHOP or with purine analogues, or bendamustine. Allogeneic SCT can be an effective option for relapsed disease in patients who are fit enough and have a compatible donor. Maintenance rituximab may be considered after response to immunochemotherapy for relapsed disease, although there are currently no data to recommend this approach as the first-line strategy. As the optimal approach to the management of MCL is still evolving, it is critical that these patients be enrolled in clinical trials to identify better treatment options.